Navigation Links
Parkinson's Disease Community Unites to Find a Cure at the 15th Annual Parkinson's Unity Walk

First Ever Virtual Parkinson's Unity Walk Launched to Expand Participation and Donations

NEW YORK, April 9 /PRNewswire/ -- On Saturday April 25, the Parkinson's disease community will unite in New York City's Central Park for the 15th annual Parkinson's Unity Walk to raise awareness and funds for Parkinson's disease research. The two-mile walk, and educational community day, provides an opportunity for this community to come together to celebrate and recognize the more than one million Americans who are affected by Parkinson's disease and their families and friends.

"This year's Walk is a special one -- it marks 15 years since the inception of this monumental event in the Parkinson's community. At the first walk there were 200 participants, last year more than 10,000 people came from across the United States to fight to cure Parkinson's disease and to connect with others whose lives are affected by the disease," said Carol Walton, executive director of the Parkinson's Unity Walk. "On April 25, we will walk to eradicate Parkinson's disease, walking to provide hope, walking to find a cure."

Together, the Parkinson's Unity Walk and Boehringer Ingelheim Pharmaceuticals, Inc., the proud partner and premier sponsor for the ninth year, continue to support Parkinson's disease awareness and partner in the development of needed tools. Understanding that, given the current economic climate, many people who want to attend the event in Central Park this year may not be able to do so, the pair teamed up to create the first ever Virtual Parkinson's Unity Walk. This year, participants can walk virtually with the thousands of others who will be walking in Central Park, by signing up at The website includes an interactive map of the United States that will highlight the locations of "virtual walkers," helping to illustrate the far-reaching impact of the Unity Walk and Parkinson's disease.

"The Parkinson's Unity Walk provides the perfect opportunity for Boehringer Ingelheim to continue our commitment to helping those who are touched by Parkinson's gain the resources they need to help manage the condition. We are thrilled to be in our ninth year as proud partner and premier sponsor of the Walk," commented Albert Ros, executive vice president at Boehringer Ingelheim Pharmaceuticals, Inc.

To commemorate the 15th anniversary of the Parkinson's Unity Walk, the organization is asking donors to consider "stepping it up" by increasing their donations by $15 or 15 percent more than the amount donated in 2008. As an incentive, donors who are able to increase donations by this amount will be eligible to participate in a raffle drawing for a dream vacation, valued at $5,000. In addition, all fundraisers who raise $1,000 or more will receive a custom 18-ounce travel mug with a full color photo of the Parkinson's Unity Walk.

"The Unity Walk inspires a spirit of renewed hope for everyone connected to Parkinson's disease," said Marlene Kahan, a community advocate, Unity Walk participant and person living with Parkinson's disease. "Whether at home or in Central Park, a single step can truly change the life of a person with Parkinson's disease."

The Unity Walk is also expected to draw impromptu attendance from celebrity supporters. To receive more information on Parkinson's disease, the raffle and give-a-ways, and the Parkinson's Unity Walk, or to lend support and donate, please visit or call 1-866-PUW-WALK (789-9255).

About Parkinson's Disease

Parkinson's disease is the second most common chronic neurological disorder in older adults after Alzheimer's, affecting approximately one percent of people over age 60. Approximately 15 percent of patients develop Parkinson's disease before the age of 50. Every nine minutes someone is diagnosed with Parkinson's disease. Symptoms include tremor, muscle rigidity, slowed motion, shuffling gait, and a loss of facial expression. The symptoms vary from patient to patient, but become more severe over time.

About Parkinson's Unity Walk

Founded in 1994 by Margot Zobel, the Parkinson's Unity Walk is an annual event where the entire Parkinson's community gathers with the goal of not only raising awareness of the condition, but of raising donations for research. The Parkinson's Unity Walk has made a significant impact on the Parkinson's disease community since its inception, raising more than $9 million for Parkinson's research by uniting the community under a common goal of winning the war against Parkinson's disease. Support for the Walk has grown considerably each year -- from 200 participants at the first walk in 1994, to more than 10,000 last year. The event unites the strength and spirit of the seven major Parkinson's disease organizations: American Parkinson Disease Association, National Parkinson Foundation, Parkinson's Action Network, Parkinson's Disease Foundation, The Michael J. Fox Foundation for Parkinson's Research, The Parkinson Alliance, and the Parkinson's Institute. With 100 percent of donations given to research, the Unity Walk provides the public with an opportunity to help the Parkinson's community and change the lives of the millions of people suffering from the disease.

SOURCE Parkinson?s Unity Walk
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HBO, UCSD Shiley-Marcos Alzheimers Disease Research Center, The Alzheimers Association San Diego/Imperial Chapter and The Neurosciences Institute Present an Advance Screening of THE ALZHEIMERS PROJECT: MOMENTUM IN SCIENCE
2. HealthMapRx, Mirixa and the City of Asheville Announce New Partnership to Improve Health & Healthcare Savings of Beneficiaries With Chronic Diseases
3. Parkinsons disease medication triggers destructive behaviors
4. Bipartisan Coalition Forms to Call for Chronic Disease to be Key Focus of Health Reform in Connecticut and Nationally
5. Recovered Lyme Disease and US Track and Field Athlete Attends Movie Premiere of LymeLife
6. Smoking Ups Infection Risk for Lung Disease Patients
7. HBO, Gladstone Institute of Neurological Disease, UC Davis Alzheimers Disease Center, UCSF Memory & Aging Center and The Alzheimers Association, No. Cal. Present an Advance Screening of THE ALZHEIMERS PROJECT: Momentum In Science
8. New, simple method identifies preterm infants at risk of eye disease
9. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
10. American Heart Association Statement Gives Guidance on Minimally Invasive Procedures to Treat Diseased Brain Vessels
11. Avastin effective at delaying brain tumor progression in recurrent disease
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics has ... dry eye treatments based on a charged hydrophilic ... delivery CDMO.  The product has been shown to ... previously published.  Mark Mitchnick , MD, CEO ... protection to additional polymers in conjunction with a ...
(Date:12/1/2015)... , December 1, 2015 --> ... report "Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, ... Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020", ... to reach USD 73,529.2 Million by 2020 from USD 40,281.6 ... to 2020. Browse 37 ...
(Date:12/1/2015)... HERTFORDSHIRE, England , BANGALORE, India ... 2015  Mylan N.V. (NASDAQ, TASE: MYL) today announced ... upon regulatory approval and for developing country markets funded ... + Lamivudine 300 mg + Efavirenz 400 mg) for ... Clinton Health Access Initiative (CHAI) to develop TLE400. The ...
Breaking Medicine Technology: